The assignee for this patent, patent number 8507446, is
Reporters obtained the following quote from the background information supplied by the inventors: "The present disclosure relates to liver disease, and more particularly to the field of liver cirrhosis. The present disclosure relates to the use of molecules useful for the manufacture of a medicament for treating liver cirrhosis.
"It is well known that liver is an organ having an extremely high ability of regenerating itself. However, in a case of chronic hepatic disease, liver undergo fibrosis during the regeneration process after continuous necrosis of hepatocytes, resulting in the suppression of normal hepatocyte regeneration. This may be due to an increase in extracellular matrix secreted by the activated hepatic stellate cells (HSCs) that involves in hepatic fibrosis. When HSCs are activated, they express .alpha.-smooth muscle actin and acquire smooth muscle property, whereby transforming themselves into myofibroblast-like cells.
"Accordingly, if an agent or a molecule may inactivate HSCs, and/or revive liver regeneration process in patients having chronic cirrhosis condition, such agent or molecule represents a potential lead compound for the development of a medicament for treating liver cirrhosis."
In addition to obtaining background information on this patent, NewsRx editors also obtained the inventors' summary information for this patent: "The present disclosure is based on the finding that PEDF-derived peptides may inactivate hepatic stellate cells (HSCs) or enhance replication or self-renewal activity of liver-derived progenitor cells (LDPCs) and thereby suppress hepatic fibrosis, promote liver regeneration and normalize the liver. The PEDF-derived peptides of this invention are, therefore, useful as an agent or a medicament for treating liver cirrhosis.
"Accordingly, it is therefore an object of the present disclosure to provide a pharmaceutical composition for treating liver cirrhosis. The pharmaceutical composition includes an effective amount of a polypeptide having an amino acid sequence at least 90% identical to SEQ ID: 1 or SEQ ID NO: 2, or a plasmid nucleic acid encoding the polypeptide and a pharmaceutically acceptable carrier; wherein the polypeptide is capable of inactivating hepatic stellate cells (HSCs) or enhancing the replication of liver-derived progenitor cells (LDPCs).
"According to one embodiment of the present disclosure, the plasmid nucleic acid is an adeno-associated viral vector. The polypeptide having an amino acid sequence at least 90% identical to SEQ ID: 1 is capable of inactivating HSCs by diminishing the levels of alpha-smooth muscle actin (a-SMC), collagen type I and monocyte chemoattractant protein-1 (MCP-1) as compared with that of the control; whereas the polypeptide having an amino acid sequence at least 90% identical to SEQ ID: 2 is capable of inducing self-renewal or replication of LDPCs. In one preferred embodiment, the polypeptide of SEQ ID NO: 1 is 34-mer PEDF, which corresponds to the segment of PEDF from amino acid residues 44 to 77; and the polypeptide of SEQ ID NO: 2 is 44-mer PEDF, which corresponds to the segment of PEDF from amino acid residues 78 to 121.
"In another aspect, the present disclosure provides a method of treating liver cirrhosis in a subject. The method includes the step of administering to the subject in need thereof the pharmaceutical composition of this invention. In one preferred embodiment, the pharmaceutical composition of the present disclosure is administered parenterally every 1 to 10 days with a dose of 0.25 to 2.5 .mu.g polypeptide/Kg of body weight or 10 .mu.g to 1 mg plasmid nucleic acid/Kg body weight for at least 1 to 10 times. The subject is a mammal, preferably a human.
"These and other features, aspects, and advantages of the present disclosure will become better understood with reference to the following description and appended claims."
For more information, see this patent: Shih, Shou-Chuan; Tsao, Yeou-Ping; Ho, Tsung-Chuan. Use of PEDF-Derived Polypeptides for Treating Liver Cirrhosis. U.S. Patent Number 8507446, filed
Keywords for this news article include: Biotechnology, Peptides, Proteins, Amino Acids, Gene Therapy, Bioengineering, Hepatic Stellate Cells,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- TFA Recruiting DACA Recipients
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- Scotch Whisky Sales Raise Distillers' Spirits
- Holiday Shopping Off to a Slow Start This Season
- Health Coverage Disparities Emerge Among States
- Podesta Likely to Reject Keystone XL
- Fake Deaf Interpreter Was Hallucinating, Has Schizophrenia
- Tea Party Glum in Face of Bipartisan Budget Deal